BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20730884)

  • 1. Treatment of childhood kaposiform hemangioendothelioma with sirolimus.
    Blatt J; Stavas J; Moats-Staats B; Woosley J; Morrell DS
    Pediatr Blood Cancer; 2010 Dec; 55(7):1396-8. PubMed ID: 20730884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
    Jahnel J; Lackner H; Reiterer F; Urlesberger B; Urban C
    Klin Padiatr; 2012 Oct; 224(6):395-7. PubMed ID: 23070861
    [No Abstract]   [Full Text] [Related]  

  • 3. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
    Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
    J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
    Wang H; Guo X; Duan Y; Zheng B; Gao Y
    Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful management of a retroperitoneal kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using alpha-interferon.
    Harper L; Michel JL; Enjolras O; Raynaud-Mounet N; Rivière JP; Heigele T; De Napoli-Cocci S
    Eur J Pediatr Surg; 2006 Oct; 16(5):369-72. PubMed ID: 17160787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
    Ji Y; Chen S; Yang K; Xia C; Peng S
    J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon.
    Mariani LG; Schmitt IR; Garcia CD; Kiszewski AE
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27810. PubMed ID: 31087627
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful Management of Pancreatic Kaposiform Hemangioendothelioma With Sirolimus: Case Report and Literature Review.
    Wang C; Li Y; Xiang B; Li F; Chen S; Li L; Ji Y
    Pancreas; 2017; 46(5):e39-e41. PubMed ID: 28426496
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful management of Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using vincristine and ticlopidine.
    López V; Martí N; Pereda C; Martín JM; Ramón D; Mayordomo E; Jordá E
    Pediatr Dermatol; 2009; 26(3):365-6. PubMed ID: 19706115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
    Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
    Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of kaposiform haemangioendothelioma successfully and safely treated with sirolimus.
    Wlodek C; Burt H; Shaw L
    Clin Exp Dermatol; 2017 Oct; 42(7):825-827. PubMed ID: 28703334
    [No Abstract]   [Full Text] [Related]  

  • 12. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms.
    Iacobas I; Simon ML; Amir T; Gribbin CE; McPartland TG; Kaufman MR; Calderwood S; Nosher JL
    Clin Imaging; 2015; 39(3):529-32. PubMed ID: 25662209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of kaposiform lymphangiomatosis with sirolimus.
    Wang Z; Li K; Yao W; Dong K; Xiao X; Zheng S
    Pediatr Blood Cancer; 2015 Jul; 62(7):1291-3. PubMed ID: 25598153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of sirolimus treatment for refractory kaposiform hemangioendothelioma with exacerbation of the disease 10 years after initial diagnosis.
    Sakata N; Suenobu SI; Okano M; Ueda S; Kimura M; Takemura T
    Rare Tumors; 2018; 10():2036361318776185. PubMed ID: 29872523
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Russell TB; Rinker EK; Dillingham CS; Givner LB; McLean TW
    Pediatrics; 2018 Apr; 141(Suppl 5):S421-S424. PubMed ID: 29610164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus.
    Wang Z; Li K; Dong K; Xiao X; Zheng S
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):72-3. PubMed ID: 24309604
    [No Abstract]   [Full Text] [Related]  

  • 17. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment.
    Hermans DJ; van Beynum IM; van der Vijver RJ; Kool LJ; de Blaauw I; van der Vleuten CJ
    J Pediatr Hematol Oncol; 2011 May; 33(4):e171-3. PubMed ID: 21516018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.
    Kai L; Wang Z; Yao W; Dong K; Xiao X
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):471-6. PubMed ID: 24464150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma.
    Tasani M; Ancliff P; Glover M
    Br J Dermatol; 2017 Dec; 177(6):e344-e346. PubMed ID: 28485019
    [No Abstract]   [Full Text] [Related]  

  • 20. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with embolization and vincristine in two newborns.
    Garcia-Monaco R; Giachetti A; Peralta O; Napoli N; Lobos P; Gioseffi L; Mariani G
    J Vasc Interv Radiol; 2012 Mar; 23(3):417-22. PubMed ID: 22365299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.